S.3474 adds a new Chapter XI to the Federal Food, Drug, and Cosmetic Act and creates a comprehensive federal regulatory structure for cannabinoid products. The bill defines “cannabinoid” and “cannabinoid product,” requires domestic and foreign facilities that manufacture or import cannabinoid products to register with FDA, imposes mandatory testing and good‑manufacturing/testing practice requirements, and sets labeling, serving-size, and packaging rules.
It also gives FDA recall, inspection, seizure, and civil‑penalty authorities specific to cannabinoid products.
Beyond product rules, the bill funds public‑health surveillance and prevention programs (including grants to reduce underage use), orders interagency work on THC‑containing beverages, and directs multi‑year research and grant programs to address cannabis‑impaired driving. For industry, regulators, and compliance teams, the bill turns varied state frameworks into a federal baseline with concrete testing, labeling, and enforcement mechanics that will drive immediate operational changes for producers, labs, and retailers.
At a Glance
What It Does
The bill incorporates cannabinoid products into the FD&C Act, establishing definitions, adulteration/misbranding standards, registration and listing obligations for facilities, mandatory laboratory testing and accreditation requirements, product standards with serving‑size limits, and new enforcement tools including recall authority and civil monetary penalties. It also prohibits certain flavored electronic cannabinoid delivery systems and requires a universal product symbol.
Who It Affects
Licensed cultivators and processors, manufacturers of ingestible and inhalable cannabinoid products, CBD/hemp product producers, testing laboratories and accreditation bodies, retailers (including remote sellers), state regulators, and Federal agencies (FDA, USDA, DEA, DOJ, TTB, DOT).
Why It Matters
The bill replaces patchwork state approaches with a federal baseline for safety, labeling, testing, and age‑based sale restrictions—changing compliance obligations for product formulation, packaging, lab relationships, recordkeeping, and interstate distribution. It also mobilizes federal funding for surveillance, underage‑use prevention, and impaired‑driving research that will inform enforcement and public‑education strategies.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
S.3474 treats cannabinoid products—defined to include hemp‑derived cannabinoids intended for use on or in humans or animals—as a distinct class under the FD&C Act. The bill creates a new statutory chapter that sets out what makes a cannabinoid product adulterated or misbranded, adds tailored labeling requirements (front‑of‑package cannabinoid disclosure, milligram counts per serving, safety warnings for special populations, universal symbol), and forbids certain product forms (for example, gummies shaped like characters) or improper resemblance to child‑targeted foods.
Every enterprise that manufactures, imports, packages, or holds cannabinoid products for commercial distribution must register facilities with FDA within tight deadlines and keep a product listing up to date; FDA will operate an online portal, assign registration numbers, and may charge a registration fee (the bill caps the initial fee and indexes it). The statute requires adoption of good manufacturing and good testing practices and mandates that finished products be tested by accredited laboratories using validated methods with specified testing scopes (pesticides, solvents, heavy metals, foreign matter, potency) and disposal rules for noncompliant samples.To limit youth access and accidental exposures, the bill directs FDA to issue rules on remote sales and mandatory age verification, requires tamper‑evident and child‑resistant packaging options, prescribes serving‑size ceilings for product categories (edibles, inhalables, topicals, drinks) when states have no rules, and bans flavored electronic cannabinoid delivery systems while permitting limited terpene use under strict concentration caps.
FDA gains recall and suspension powers specific to cannabinoid facilities and a civil penalty regime for violations tied to registration, adulteration, misbranding, and unlawful sales.Complementing product rules, the bill funds public‑health surveillance at CDC and HRSA, creates grant programs to prevent underage cannabis use, and establishes a multi‑year DOT/NHTSA research program on cannabis‑impaired driving—including a National Roadside Survey and studies to assess correlation between THC measures and impairment—that can drive a model impairment standard. It also instructs a joint agency report on a federal framework for THC‑containing beverages modeled after alcohol regulation (roles for USDA, FDA, DOJ, and TTB).
The Five Things You Need to Know
Facility registration deadlines: existing facilities must register with FDA within 90 days of enactment; new facilities must register within 30 days of first engaging in covered activity; registrations must be renewed by December 31 of each even‑numbered year.
Registration fee: FDA may charge a fee due at submission—capped at $500 for FY2026 and inflation‑adjusted thereafter, with a 75% refund for denied or withdrawn registrations.
Serving‑size defaults: where states lack rules, the bill caps THC at 5 mg per serving and 50 mg per container for edibles, inhalables, and topicals (drinkable products limited to 5 mg per serving and 10 mg per container).
Laboratory standards: finished products must be tested in labs certified/accredited in the producing State and meet accreditation requirements (e.g.
ISO 17025 or successor); an FDA/DEA memorandum will define accreditation criteria and permit certain USDA/HHS‑registered labs to qualify.
Civil penalties and enforcement: FDA can seek civil penalties up to $15,000 per violation (up to $15M per proceeding), enhanced penalties for knowing violations up to $250,000 per violation (or escalating amounts for continued noncompliance), and impose no‑sale orders at retail for repeated violations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
When a cannabinoid product is ‘adulterated’
This provision adapts the FD&C adulteration framework to cannabinoid products. In addition to standard contamination and insanitary manufacturing triggers, the bill explicitly treats products manufactured from artificially or synthetically derived cannabinoids as adulterated and links adulteration to state THC limits—if a State has no THC law, federal standards apply. Practically, that means formulators using semi‑synthetic or synthetic cannabinoid inputs face a high bar: FDA can deem such products tainted and remove them from commerce absent specific regulatory authorization.
Detailed misbranding and labeling obligations
This section mandates a long list of label elements for finished cannabinoid products: a front‑of‑package statement that the product contains cannabinoids, manufacturer contact details, net quantity, form, serving‑size directions and milligrams of THC and other cannabinoids per serving, safety warnings for children, pregnant/nursing persons, drug‑interaction language, an FDA non‑evaluation disclaimer for non‑drugs, the universal symbol, and disclosure of where safety test results can be found. FDA can add additional labeling requirements by regulation. The statute also bans product forms likely to appeal to children (e.g., character shapes) and constrains gummy shapes and eye/nasal/ injectable presentations—items that compliance and packaging teams must consider immediately.
Facility registration, product listing, and inspection
Covered entities—domestic and foreign facilities engaged in manufacturing, packaging or importing cannabinoid products—must register on an FDA portal, provide facility and contact details, list all brands and labels (kept confidential), and certify access for inspection. FDA will publish a non‑public list of registered facilities, may charge the registration fee, and can suspend registrations if a facility’s products present a reasonable probability of serious adverse effects. The statute sets short procedural timelines for suspension notices, corrective‑action plans, and informal hearings—meaning firms must be ready with traceability and corrective plans to avoid suspension and distribution stoppages.
Sales, age verification, GMP, testing, and packaging rules
FDA gets several operational levers here. It must issue rules on remote sales and age verification within three years, including online ID checks and shipment/time‑of‑purchase verification to prevent sales to anyone under 21; it can require tamper‑evident and child‑safe packaging for larger containers; and it must finalize current good manufacturing practice and good testing practice rules (GMP/GTP) within months to a year. Testing requirements are specific: validated sampling, analytical methods (peer‑reviewed or AOAC‑type verification), potency analysis that cannot be manipulated, and testing scopes including pesticides, heavy metals, solvents, foreign matter, and semi‑synthetic byproducts. FDA can require labs to be accredited to standards such as ISO 17025.
Product standards, categories, and default serving sizes
Within a year FDA must adopt product standards that distinguish categories (edibles, inhalables, topicals, drinkables) and address ingredients, yields, constituent interactions, and reductions of harmful constituents including smoke components. Importantly, FDA may set default serving‑size ceilings that apply where States lack rules: generally 5 mg THC per serving with container caps (50 mg for most categories, 10 mg for drinkables). States can continue to set stricter rules, but the federal defaults create a uniform floor for interstate commerce.
Recall authority, records, and flavored vaping prohibition
FDA can issue immediate cease‑distribution orders when products present a reasonable probability of causing serious adverse effects, provide expedited hearings, and, if warranted, convert orders into recalls with consumer notice (excluding retrieval from individuals). Manufacturers and importers must maintain FDA‑specified records and report corrective actions and market removals. Separately, the bill bans most added flavors in electronic cannabinoid delivery systems, while allowing terpenes under strict concentration limits (5–6% depending on naturally occurring vs added), an important restriction for vape‑product formulators and accessory manufacturers.
Public‑health surveillance, underage‑use grants, and impaired‑driving programs
Title II authorizes expanded surveillance funding at HHS to collect data on cannabis and polysubstance use and creates competitive grants to states, tribes, and community groups to prevent underage use (with prioritization for underserved communities). Title III directs multi‑year DOT/NHTSA research: a National Roadside Survey, studies examining THC levels vs impairment, evaluation of field sobriety tests, and a state grant program to prevent cannabis‑impaired driving with matching rules tied to open‑container laws. The titles also appropriate funds to support these programs and require interagency coordination on THC beverages modeled on alcohol regulation.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Consumers seeking safer products — will get standardized labeling, required potency disclosure, safety warnings, and access to testing information that supports informed consumption decisions.
- Public‑health agencies and researchers — receive new surveillance funding, grants, and structured data (including a National Roadside Survey) to study underage use, health impacts, and impaired‑driving risks.
- Accredited laboratories and testing‑service providers — stand to gain business from mandated testing and accreditation requirements, particularly labs that meet ISO 17025 or state accreditation standards.
- State regulators and courts — benefit from a federal baseline that clarifies product categories and testing expectations while retaining authority to adopt stricter rules and to tax products as they see fit.
- Retailers that maintain compliance programs — will gain marketplace advantages by avoiding no‑sale orders and penalties and by marketing clearly labeled, tested products to regulated adult consumers.
Who Bears the Cost
- Small producers and craft manufacturers — face new compliance costs (facility registration, GMP upgrades, third‑party testing fees, label redesign, serving‑size reformatting) that could be disproportionately large relative to margins.
- Testing laboratories that are not accredited — must invest in accreditation (ISO 17025, quality systems) or partner with accredited labs; where DEA or state registration is disputed, labs may need legal and administrative support.
- State agencies and courts — will absorb administrative burdens to coordinate with federal surveillance programs, implement enforcement priorities, and handle specialized impaired‑driving prosecutions and training.
- Retailers and e‑commerce platforms — must implement robust age‑verification and traceability systems for remote sales and risk being subject to no‑sale orders or civil penalties for repeated violations.
- FDA and other federal agencies — need funding and staffing to stand up registration portals, inspection programs, rulemakings, lab accreditation processes, and interagency beverage regulation workstreams.
Key Issues
The Core Tension
The bill’s central dilemma is between a uniform federal safety baseline (which promotes interstate commerce, consumer information, and product safety) and the technical and economic realities of a diverse industry and state regulatory experiments: federal standardization simplifies some compliance questions but imposes substantial testing, labeling, and accreditation costs, and its partial preemption of labeling while leaving other state controls intact produces friction for manufacturers and regulators.
The bill attempts a federal harmonization of safety, labeling, and testing for cannabinoid products, but it creates several implementation pinch points. First, the statutory carveouts and definitions (e.g., excluding drugs and devices, distinguishing semi‑synthetic vs artificially synthetic cannabinoids) leave room for regulatory debate about which inputs or conversion processes are permitted; determining whether a product is a semi‑synthetic cannabinoid or an adulterated synthetic derivative will require technical guidance and likely litigation.
Second, the laboratory accreditation regime is ambitious but relies on interagency cooperation (FDA, DEA, USDA) and ISO‑based accreditation; states that operate their own lab networks may face transition costs and disputes over recognition of state vs federal accreditation. Third, the bill empowers FDA to set defaults (serving sizes, packaging rules, age verification for remote sales) while preserving state authority to impose more stringent rules except for labeling where states are expressly preempted from non‑identical labeling regimes.
That partial preemption creates tension: manufacturers must comply with a single federal label standard but navigate a patchwork of state restrictions on sale, packaging, and distribution.
Enforcement poses practical tradeoffs. FDA’s new civil penalties, suspension, and no‑sale authorities are strong tools, but resource‑constrained states and FDA will need operational plans to implement quick suspensions and recalls without disrupting legal supply chains.
The impaired‑driving provisions fund research to produce a usable impairment standard, but the science linking THC concentration to impairment remains complex; any future model standard will have to reconcile pharmacokinetic variability, chronic user tolerance, and differences between oral and inhaled products. Lastly, the bill funds surveillance and grants but leaves many administrative details—matching funds, grant prioritization, and interagency roles—to future rulemaking and memoranda, creating near‑term uncertainty for program implementers and industry planning.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.